Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) just unveiled an update.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., has submitted a post-hearing information pack (PHIP) to the Hong Kong Stock Exchange in connection with its proposed spin-off and separate listing. The move is subject to approval by the Stock Exchange and other conditions, and if successful, it could lead to a preferential offering and a global offering. Stakeholders are advised to exercise caution as there is no guarantee that the spin-off and listing will proceed.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company incorporated in Bermuda, primarily operating in the pharmaceutical industry. It focuses on the development and distribution of pharmaceutical products and is listed on the Hong Kong Stock Exchange under stock code 0460.
Average Trading Volume: 98,810,504
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.58B
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.